Floatz logo

Bms-907351

Stage III Bladder Cancer AJCC v8

National Cancer Institute (NCI)Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Stage III Bladder Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 2BB
Carboplatin
Iambic Therapeutics, Inc
Phase 2BB

View all 45 →

Same molecule, other indications

Bms-907351 is also rated in:

renal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →